Valeda Light Delivery System for AMD

Overview
The Valeda Light Delivery System authorized by the first U.S. Food and Drug Administration (FDA) for treatment of dry age-related macular degeneration (AMD). People with early to intermediate stages of dry AMD are eligible for this treatment, especially those with initial vision loss. 

The Valeda Light Delivery System uses a technique called photobiomodulation, which delivers specific types of light to stimulate (activate) cells in the retina, the part of the eye that senses light. This light targets tiny parts of the cell called mitochondria, which act like batteries to power the cell. By boosting cell activity, Valeda helps keep retinal cells healthy and may slow down damage. This could improve vision or prevent further vision loss in people with dry AMD."

How is it used?
The Valeda Light Delivery System is administered by trained health care professionals as an in-office procedure. A person will typically undergo a series of treatments during which the device delivers light in a sequence of wavelengths directly to the retina through a noninvasive process. The full treatment involves repeated sessions scheduled over several weeks to sustain visual improvements. Treatment must be completed as directed by a health care provider​​.

Side effects
In clinical trials, Valeda was found to be safe, with no side effects reported. The product documentation does caution against use in individuals with known photosensitivity (sensitivity to light) to certain wavelengths used in the treatment and in those who have used photosensitizing agents in the past 30 days.

For more information about this treatment, visit:

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients To Improve Vision — LumiThera

LumiThera’s Valeda Light Delivery System Receives Marketing Authorization From FDA — Ophthalmology Times

Valeda Light Delivery System User Manual — Valeda